An interventional study of Cardiac Rehabilitation (CR): Experimental and Treatment as usual: Control in Congenital Heart Disease, Cardiomyopathies and Cardiac Arrythmias, sponsored by Greater Manchester Mental Health NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 11 Years to 16 Years. Per ClinicalTrials.gov, last updated 2024-03-07.
Sponsored by Greater Manchester Mental Health NHS Foundation Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Heart Defects, Congenital with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Heart Defects, Congenital · United Kingdom.
Among the 32 studies in Heart Defects, Congenital with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 24th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →10 of the 32 studies in Heart Defects, Congenital with a site in United Kingdom are open now. Recruiting first, the newest first:
Liverpool Heart and Chest Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18+
University of Leicester · Sites in United Kingdom
Ages 16–50 · Healthy volunteers
Leiden University Medical Center · Sites in United Kingdom, United States, Germany and 2 more countries
Ages 18+
Occlutech International AB · Sites in United Kingdom, Ireland, Turkey
Ages 3 mo–80 yrs
Fondation Hôpital Saint-Joseph · Sites in United Kingdom, France, Germany and 2 more countries
Ages up to 3
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 11 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 6 · Phase 4 2
First in 2000; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 50 across the 17 interventional studies, 300 across the 14 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 32 have an industry lead sponsor. The 10 most frequent:
Greater Manchester Mental Health NHS Foundation Trust is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Greater Manchester Mental Health NHS Foundation Trust has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Defects, Congenital with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07697755University of GlasgowInteroceptive Intervention for Congenital Heart Disease | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Heart Defects, Congenital with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Heart problems are amongst the most common physical illnesses in children and young people (CYP). They can be present from birth or develop as CYP get older and are linked to increased physical and psychological difficulties overprotection from caregivers and healthcare providers and reduced quality of life.
While adults are offered exercise classes and lifestyle advice after a heart problem, CYP with heart problems are not. Improving health behaviours in people with heart problems is vital, improves quality of life and reduces additional illnesses (i.e obesity, diabetes).
Approximately 1 in 3 CYP with heart problems have anxiety and/or depression so it is also important to support their mental health. One way to do this is to develop and test the acceptability and feasibility of a trial of cardiac rehabilitation (CR) consisting of exercise with mental health support for CYP.
The aim is to develop and test the feasibility and acceptability of a trial of a cardiac rehabilitation programme for CYP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants meeting the following inclusion criteria and aged between 11-16 years old will be eligible:
Inclusion Criteria:
Diagnosed with at least one of the following:
Exclusion Criteria:
Those with a formal diagnosis or under assessment for any above exclusion criteria will be excluded.
Participants allocated to the intervention group will receive a cardiac rehabilitation (CR) programme which will involve education, exercise, and a psychological component.
Behavioral: Cardiac Rehabilitation (CR): Experimental
Participants allocated to the control group will receive treatment as usual.
Behavioral: Treatment as usual: Control
CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.
Treatment as usual will include routine clinical outpatient management.
Recruitment Rate (Feasibility Outcome)
Feasibility will be assessed using recruitment rate (i.e., number of patients consented and randomized, number of patients declined the study).
Time frame: Date of Baseline Assessment to end of follow-up (24 week follow up)
Retention Rate (Feasibility Outcome)
Feasibility will be assessed using retention rates (i.e., number of patients withdrawn from the study, lost to follow up)
Time frame: Date of Baseline Assessment to end of follow-up (24 week follow up)
Intervention Attendance (Feasibility Outcome)
Feasibility will be assessed using participant attendance at intervention (i.e., number of sessions attended at the intervention).
Time frame: Date of Baseline Assessment to end of follow-up (24 week follow up)
Acceptability of the Intervention
Acceptability of the intervention will be assessed in qualitative semi-structured interviews with children and young people, caregivers, and healthcare professionals, which will assess individuals views on the intervention, targets for improvement, and perceived acceptability of the components of the cardiac rehabilitation programme.
Time frame: Date of Baseline Assessment to end of follow-up (24 week follow up)
Strength and Difficulties Questionnaire (SDQ)
The SDQ measures psychological wellbeing across five subscales: emotion, hyperactivity, conduct, peer relations and pro-social behaviour. The SDQ can be completed by CYP and caregivers. Score for the subscales range from 0-10, with a total difficulties score (0-40) generated by summing together the scores from all subscales except the pro-social subscale. Higher scores on the pro-social scale reflect strengths whereas higher scores across other subscales reflect difficulties.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Paediatric Quality of Life (PedsQol)
The PedsQol is a 23 item measures of health related quality of life, and includes four subscales: physical, emotional, social and school functioning. The questionnaire is commonly used in paediatric cardiology. The PedsQol will be completed by CYP. The items are scores from 0 (Never) to 4 (Almost always). Total scores range from 0-100, with higher scores indicating better quality of life.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Six minute walk test (6MWT)
The 6MWT is used to assess aerobic capacity and endurance. Performance on the 6MWT has been predictive of morbidity and mortality whereby poorer performance is associated with increased mortality.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Incremental Shuttle Walk Test (ISWT)
The ISWT is used to measure maximal exercise capacity. The ISWT is a 12-level test (1 min at each level), whereby participants walk up and down a 10, course with increasing accelearion of 0.17 m/s up to a maximum speed of 2.37 m/s. Walking speed is dicated by an audio signal. The test ends when the subject has a heart rate greater than 85% of their predicted maximum, is limited by dyspnoea or when the participant is unable to maintain the required speed and doe snot complete a shuttle for second consecutive time. The distance covered from the number of shuttles will be calculated.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Physical Activity Monitoring
Participants will wear an accelerometer (Actigraph) for 5 days to monitor physical activity levels at each assessment.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Metacognition Questionnaire-Adolescent (MCQ-A)
The MCQ-A assesses metacognitive beliefs (beliefs about thinking) across five subscales (uncontrollability of worry, need to control thoughts, cognitive self-consciousness, positive beliefs about worry, and cognitive confidence). The measure contains 30 items and is scored on a likert scale from 1 (do not agree) to 4 (agree very much). Total scores range from 30-120 and 6 to 30 for each subscale. Greater scores indicate greater maladaptive metacognitive beliefs. The measure and will be completed by CYP.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Child Health Utility-9D (CHU-9D)
The CHU-9D measures quality of life using nine dimensions (worried, sad, pain, tired, annoyed, schoolwork/homework, sleep, daily routine, and ability to join in activities). Each item has 5 levels ranging from no problems to inability to do the item. Responses will be used to generate utility values in the health economic evaluation. The CHU-9D will be completed by CYP.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Health and Social Care Service-Use Questionnaire
The questionnaire will include questions about whether the child has used any primary, secondary, or community-based health and social care and how often they used the service in the last 16 weeks (baseline study visit) or since the last assessment (follow-up study visits). The questionnaire will be developed from existing child relevant service use questionnaires held by the co-applicants and through discussion with the patient and public involvement representative, parent advisory group and clinical members of the study team. This will be completed by parents/primary caregivers. The responses given and the patient feedback will be used to further refine the health-resource use questionnaire ahead of the definitive study.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Demographics Questionnaire
The demographics questionnaire will collect variables such as participants age, sex, weight, height, BMI, type of heart problem, comorbid mental and physical illnesses, ethnicity, medication, socioeconomic status, parental occupational status. This will be completed by the parents/primary caregivers.
Time frame: Baseline, 12 weeks (end of treatment), and 24 weeks (follow-up)
Started Mar 2024 (actual). Primary completion is estimated for Aug 2024, 5 months after the start.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 5 months is below that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Greater Manchester Mental Health NHS Foundation Trust